Advertisement


Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Advertisement